Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology

ABSTRACT: After 2 and 12 weeks of treatment, we observed significant reductions of 51% and 72%, respectively, in SCORAD scores. Clinical improvements were associated with significant gene expression changes in lesional but also nonlesional skin, particularly reductions in levels of TH2-, TH22-, and some TH17-related molecules (ie, IL-13, IL-22, CCL17, S100As, and elafin/peptidase inhibitor 3), and modulation of epidermal hyperplasia and differentiation measures.

ORGANISM(S): Homo sapiens

PROVIDER: GSE58558 | GEO | 2014/06/17

SECONDARY ACCESSION(S): PRJNA252869

REPOSITORIES: GEO